Wave Life Sciences Ltd. (NASDAQ:WVE) Expected to Post Earnings of -$0.56 Per Share

Wall Street analysts expect Wave Life Sciences Ltd. (NASDAQ:WVEGet Rating) to announce ($0.56) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Wave Life Sciences’ earnings. The lowest EPS estimate is ($0.63) and the highest is ($0.48). Wave Life Sciences reported earnings of ($0.78) per share in the same quarter last year, which indicates a positive year over year growth rate of 28.2%. The firm is scheduled to report its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Wave Life Sciences will report full-year earnings of ($1.99) per share for the current year, with EPS estimates ranging from ($2.52) to ($1.42). For the next fiscal year, analysts forecast that the business will post earnings of ($1.83) per share, with EPS estimates ranging from ($2.42) to ($0.97). Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that that provide coverage for Wave Life Sciences.

Wave Life Sciences (NASDAQ:WVEGet Rating) last released its quarterly earnings results on Thursday, March 3rd. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.14). The firm had revenue of $1.77 million for the quarter, compared to the consensus estimate of $18.14 million. Wave Life Sciences had a negative return on equity of 558.73% and a negative net margin of 275.31%. During the same quarter in the prior year, the company posted ($0.59) EPS.

WVE has been the subject of several research analyst reports. HC Wainwright reduced their price objective on shares of Wave Life Sciences from $10.00 to $8.00 in a report on Friday, May 13th. StockNews.com initiated coverage on shares of Wave Life Sciences in a report on Thursday, March 31st. They issued a “hold” rating for the company.

WVE stock traded down $0.04 during trading on Wednesday, hitting $1.23. The company had a trading volume of 1,078 shares, compared to its average volume of 520,349. The firm has a market capitalization of $75.34 million, a price-to-earnings ratio of -0.58 and a beta of 0.49. The business has a 50 day moving average of $2.03 and a 200 day moving average of $2.80. Wave Life Sciences has a fifty-two week low of $1.16 and a fifty-two week high of $7.55.

In other news, CEO Paul Bolno sold 33,501 shares of the company’s stock in a transaction dated Thursday, May 5th. The stock was sold at an average price of $1.72, for a total value of $57,621.72. Following the transaction, the chief executive officer now owns 436,825 shares in the company, valued at approximately $751,339. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Chandra Vargeese sold 16,714 shares of the company’s stock in a transaction that occurred on Thursday, May 5th. The stock was sold at an average price of $1.72, for a total value of $28,748.08. Following the sale, the insider now directly owns 111,095 shares of the company’s stock, valued at approximately $191,083.40. The disclosure for this sale can be found here. Insiders sold a total of 55,236 shares of company stock valued at $95,006 over the last three months. 28.40% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently modified their holdings of the business. Mirabella Financial Services LLP acquired a new position in Wave Life Sciences in the first quarter worth $44,000. Goldman Sachs Group Inc. increased its holdings in shares of Wave Life Sciences by 274.8% in the first quarter. Goldman Sachs Group Inc. now owns 421,412 shares of the company’s stock worth $843,000 after acquiring an additional 308,966 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Wave Life Sciences by 450.1% in the first quarter. Renaissance Technologies LLC now owns 205,194 shares of the company’s stock worth $410,000 after acquiring an additional 167,894 shares in the last quarter. Kynam Capital Management LP grew its holdings in shares of Wave Life Sciences by 27.9% during the first quarter. Kynam Capital Management LP now owns 1,911,728 shares of the company’s stock worth $3,823,000 after buying an additional 417,134 shares in the last quarter. Finally, M28 Capital Management LP grew its holdings in shares of Wave Life Sciences by 55.4% during the first quarter. M28 Capital Management LP now owns 5,850,000 shares of the company’s stock worth $11,700,000 after buying an additional 2,084,412 shares in the last quarter. 78.68% of the stock is owned by institutional investors.

About Wave Life Sciences (Get Rating)

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression.

Read More

Get a free copy of the Zacks research report on Wave Life Sciences (WVE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.